These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26535146)

  • 1. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis.
    Alten R; Grahn A; Holt RJ; Rice P; Buttgereit F
    RMD Open; 2015; 1(1):e000134. PubMed ID: 26535146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
    Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG
    Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
    Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis.
    Rendas-Baum R; Lin X; Kosinski M; Bjorner JB; Bracher MG; Chen WH
    J Patient Rep Outcomes; 2024 Jan; 8(1):9. PubMed ID: 38252223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study.
    Dikranian AH; Mallay R; Marshall M; Francis-Sedlak M; Holt RJ
    Rheumatol Ther; 2017 Dec; 4(2):363-374. PubMed ID: 28819927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    Emery P; Blanco R; Maldonado Cocco J; Chen YC; Gaich CL; DeLozier AM; de Bono S; Liu J; Rooney T; Chang CH; Dougados M
    RMD Open; 2017; 3(1):e000410. PubMed ID: 28405473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
    BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified-release prednisone: in patients with rheumatoid arthritis.
    Henness S; Yang LP
    Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Lancet; 2008 Jan; 371(9608):205-14. PubMed ID: 18207016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
    Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A
    Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.